3D-QSAR (quantitative structure-activity relationships) studies on urea derivatives as inhibitors of p38 MAP kinase

Internet Electronic Journal of Molecular Design

Volumn 7, Issue 2, 2008, Pages 38-46

  Sarma, Rituparna ^a   Sinha, Sharat ^a   Ravikumar, Muttineni ^a   Kumar, Madala Kishore ^a   Mahmood, Shaik ^b  

^a Biocampus   (India)

^b OSMANIA UNIVERSITY   (India)

Author keywords

MFA; p38 MAP kinase; QSAR; Urea derivatives

Indexed keywords

EID: 57549084099     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. P. Sandra, J. P. Maria, M. C. Pedro, S. M. Victoria, R. G. Ana, C. Piero, M. Federico Jr., and M. Cristina, Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK, Curr. Bio. 2006, 16, 2042-2047.
2. J. C. Lee, J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, J. E. Stricker, M. M. McLaughlin, J. R. Siemens, S. M. Fisher, G. P. Livi, J. R. White, J. L. Adams, and P. R. Young, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature 1994, 372, 739-746.
3. J. Hans, J. D. Lee, L. Bibbs, and R. J. Ulevitch, A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells, Science 1994, 265, 808-811.
4. M. R. S. Nayana, Y. N. Sekhar, N. S. Kumari, S. K. Mahmood, and M. Ravikumar, CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors, Eur. J. Med. Chem. 2008, 43, 1261-1269.
5. M. R. S. Nayana and Y. N. Sekhar, Comparative Molecular Field Analysis (CoMFA) for p38 Inhibitors, Internet Electron. J. Mol. Des. 2007, 6, 385-395, http://www.biochempress.com.
6. F. M. Brennan and M. Feldman, Cytokines in autoimmunity, Curr. Opin. Immunol. 1996, 8, 872-877.
7. G. Camussi and E. Lupia, The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis, Drugs 1998, 55, 613-620.
8. C. Hansch, A quantitative approach to biochemical structure-activity relationships, Acc. Chem. Res. 1969, 2, 232-239.
9. A. R. Katritzky and E. V. Gordeeva, Traditional topological indices vs. electronic geometrical and combined molecular descriptors in QSAR/QSPR research, J. Chem. Inf. Comput. Sci. 1993, 33, 835-857.
10. H. Van de Waterbeemd, Recent progress in QSAR-technology, Drug Des. Discov. 1993, 9, 277-285.
11. Y. N. Sekhar, M. R. S. Nayana, S. K. Mahmood, and M. Ravikumar, Comparative Molecular Field Analysis on quinoline derivatives of Metabotropic glutamate receptor subtype 1, Chem. Biol. Drug Des. 2007, 70, 511-519.
12. S. M. Vadlamudi and V. M. Kulkarni, 3D-QSAR of Protein Tyrosine Phosphatase 1B Inhibitors by Genetic Function Approximation, Internet Electron. J. Mol. Des. 2004, 3, 586-609, http://www. biochempress.com.
13. P. M. Kumar, C. Karthikeyan, N. S. H. N. Moorthy, and P. Trivedi, Quantitative structure-activity relationships of selective antagonists of glucagon receptor using QuaSAR descriptors, Chem. Pharm. Bull. (Tokyo) 2006, 54, 1586-1591.
14. M. R. S. Nayana, Y. N. Sekhar, N. S. Kumari, and SK. Mahmood, 3D-QSAR CoMFA Study on Human Glutaminyl Cyclase Inhibitors, Internet Electron. J. Mol. Des. 2007, 6, 320-330, http://www.biochempress.com.
15. A. J. Hopfinger, J. S. Tokarsi, and P. S. Charifson (Eds.), Practical Applications of Computer-Aided Drug Design, Marcel Dekker, New York, 1997.
16. D. Rogers and A. J. Hopfinger, J. Chem. Inf. Comput. Sci. 1994, 34, 854.
17. Y. N. Sekhar, M. Ravikumar, M. R. S. Nayana, S. C. Mallena, and M. K. Kumar, 3D-QSAR study on triazafluorenone inhibitors of metabotropic glutamate receptor subtype 1, Eur. J. Med. Chem. 2008, 43, 1025-1034.
18. A. M. Redman, J. S. Johnson, R. Dally, S. Swartz, H. Wild, H. Paulsen, Y. Caringal, D. Gunn, J. Renick, M. Osterhout, J. Kingery-Wood, R. A. Smith, W. Lee, J. Dumas, S. M. Wilhelm, T. J. Housley, A. Bhargava, G. E. Ranges, A. Shrikhande, D. Young, M. Bombara, and W. J. Scott, p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas, Bioorg. Med. Chem. Lett. 2001, 11, 9-12.
19. D. Hammaker, S. Sweeney, and G. S. Firestein, Signal transduction networks in rheumatoid arthritis, Ann. Rheum. Dis. 2003, 62, 86-89.
20. http://www.rcsb.org, PDB 1W82.
21. J. Gasteiger and M. Marsili, A New Model for Calculating Atomic Charges in Molecules, Tetrahedron Lett. 1978, 3181-3184.
22. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy and J. J. P. Stewart, J. Am. Chem. Soc. 1985, 107, 3902.
23. V. Aparna, J. Jeevan, M. Ravi, G. R. Desiraju, and B. Gopalakrishnan, 3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment method, Bioorg. Med. Chem. Lett. 2006, 4, 1014-1020.
24. 2 version 4.8, Accelrys, San Diego, USA, http://www.accelrys.com/cerius2.